Boehringer Mannheim exercises Pace option:
This article was originally published in Clinica
Executive Summary
Boehringer Mannheim (Germany) has decided to exercise the option agreement it has with Canadian company Pace for the latter's glycogen phosphorylase (GBPP) cardiac marker test (see Clinica No 692, p 18). The decision, which comes two months before the option expires, will provide Pace with royalties.